1. Home
  2. NPWR vs PLX Comparison

NPWR vs PLX Comparison

Compare NPWR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NET Power Inc.

NPWR

NET Power Inc.

HOLD

Current Price

$1.70

Market Cap

193.9M

Sector

Energy

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.32

Market Cap

174.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPWR
PLX
Founded
2010
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.9M
174.0M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
NPWR
PLX
Price
$1.70
$2.32
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$3.50
$12.00
AVG Volume (30 Days)
554.6K
827.6K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$52,744,000.00
Revenue This Year
N/A
$36.81
Revenue Next Year
N/A
$1.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.46
$1.34
52 Week High
$5.20
$3.19

Technical Indicators

Market Signals
Indicator
NPWR
PLX
Relative Strength Index (RSI) 52.46 47.94
Support Level $1.64 $2.03
Resistance Level $1.80 $2.45
Average True Range (ATR) 0.10 0.08
MACD 0.03 0.03
Stochastic Oscillator 62.03 81.16

Price Performance

Historical Comparison
NPWR
PLX

About NPWR NET Power Inc.

NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: